A Case of Autoiminune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

被引：22

作者：

Brito, Sergio ^{[1
]}

Ferreira, Nuno ^{[1
]}

Mateus, Sofia ^{[1
]}

Bernardo, Manuela ^{[2
]}

Pinto, Beatriz ^{[3
]}

Lourenco, Ana ^{[1
]}

Grenho, Fatima ^{[1
]}

机构：

[1] Hosp CUF Tejo, Internal Med, Lisbon, Portugal

[2] Hosp CUF Tejo, Hematol & Oncol, Lisbon, Portugal

[3] Hosp CUF Tejo, Pharm, Lisbon, Portugal

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 05期

关键词：

covid-19 mrna vaccine; autoimmune hemolytic anemia; sars-cov-2; warm autoimmune hemolytic anemia; immune-mediated hemolysis;

D O I：

10.7759/cureus.15035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.

引用

页数：5

共 8 条

[1]

[Anonymous], 2021, Coronavirus Vaccine-Summary of Yellow Card Reporting-GOV.UK

[2]

[Anonymous], 2021, NOTIFICATION ADVERSE

[3] New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia [J].